Comparison of Multidrug Formulations for Anti-Hypertensive TreatmentDrashti Desai, Pravin Shende* and Gaud RS
SPP-School of Pharmacy and Technology Management, SVKM’S NMIMS, Mumbai, India
- *Corresponding Author:
- Pravin Shende
SPP-School of Pharmacy and Technology Management
SVKM’S NMIMS, Vile Parle (W), Mumbai, India
E-mail: [email protected]
Received date: October 21, 2016; Accepted date: November 08, 2016; Published date: November 18, 2016
Citation: Desai D, Shende P, Gaud RS (2016) Comparison of Multidrug Formulations for Anti-Hypertensive Treatment. J Bioequiv Availab 8:278-282. doi: 10.4172/jbb.1000309
Copyright: © 2016 Desai D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The multidrug therapy in the form of Orally Disintegrating Tablets (ODTs) is superior to control and treat high blood pressure and to decrease cardiovascular events in hypertensive patients than individual drug telmisartan, hydrochlorothiazide and amlodipine besylate to provide quick onset of action and improve drug adherence. ODT formulations of telmisartan and amlodipine besylate (F1), telmisartan and hydrochlorothiazide (F2), amlodipine besylate and hydrochlorothiazide (F3) were prepared by direct compression method and evaluated for precompression parameters and post-compression parameters. Formulation F1 showed the highest release of the drug, i.e., 80.7 ± 0.5%, whereas F2 and F3 showed 66.285 ± 0.3% and 65.182 ± 0.7% respectively for 15 min. All three formulations (F1, F2 and F3) passed the tests with disintegrating time within the limit of 20 s. The hardness of formulations was in the range of 4.33 to 5.33 kg/cm2 and the friability of all the formulations were found to be within limit of 1%. The thickness and diameter of all the formulations were found to be 0.2-0.3 cm and 0.8 cm respectively. The % dissolution efficiencies were found in the order of F1>F3>F2. All formulations were found to be stable when were maintained at 40 ± 2°C/75 ± 5% RH and 50 ± 2°C/75 ± 5% RH for 6 months. This multidrug combination therapy may serve as an alternative for conventional single pill dosage form to treat hypertension.